Delcath provides Q1 preliminary results; PDUFA date Aug 14, closes $25M financing

DELCATH SYSTEMS, INC.

FDA set PDUFA goal date of August 14, 2023 for Hepzato Kit NDA resubmission.
Closed initial $25M of up to $85M private placement led by Vivo Capital.
Amended loan with Avenue Venture to defer $4.3M in principal payments through September 2023.
Appointed John R. Sylvester as Chairman of the Board.
CHOPIN trial: 7 uveal melanoma patients had median PFS of 29.1 months at 29.1-month follow-up.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

DELCATH SYSTEMS, INC. reported preliminary financial results for first quarter ended March 31, 2023.

Period: first quarter ended March 31, 2023
Result: preliminary results

Exact text from the filing

Delcath Systems, Inc. (Nasdaq: DCTH) (Delcath or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported business highlights and certain preliminary financial results for the first quarter ended March 31, 2023.

View on SEC.gov

Browse all earnings releases →

DELCATH SYSTEMS, INC. filing history →

Source: SEC EDGAR

accession 0001193125-23-142792

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.